Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Other Non-Current Liabilities (2017 - 2025)

Seres Therapeutics (MCRB) has disclosed Other Non-Current Liabilities for 9 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 13.0% to $2.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Dec 2025, up 13.0% year-over-year, with the annual reading at $2.1 million for FY2025, 13.0% up from the prior year.
  • Other Non-Current Liabilities hit $2.1 million in Q4 2025 for Seres Therapeutics, up from $2.0 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $11.5 million in Q4 2021 to a low of $777000.0 in Q1 2021.
  • Historically, Other Non-Current Liabilities has averaged $2.6 million across 5 years, with a median of $1.8 million in 2024.
  • Biggest five-year swings in Other Non-Current Liabilities: surged 1046.06% in 2021 and later crashed 88.28% in 2022.
  • Year by year, Other Non-Current Liabilities stood at $11.5 million in 2021, then crashed by 91.64% to $961000.0 in 2022, then skyrocketed by 69.41% to $1.6 million in 2023, then increased by 12.9% to $1.8 million in 2024, then increased by 13.0% to $2.1 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for MCRB at $2.1 million in Q4 2025, $2.0 million in Q3 2025, and $2.0 million in Q2 2025.